Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Mild Depression

Status: Recruiting
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Cognitive deficits, including working memory deficits, are often present in depression and there are currently no effective pharmacological treatments targeting working memory deficits. Papassotiropoulos et al. (2024) has recently demonstrated that fampridine, a potassium channel blocker, can enhance working memory in healthy individuals with lower baseline performance, suggesting it may hold potential for addressing cognitive deficits in clinical populations. The primary aim of this study is to evaluate whether fampridine improves working memory performance in mild depression

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 30
Healthy Volunteers: f
View:

• Male or female

• Major depressive episode confirmed by the Mini-DIPS. Currently mild (MADRS: 7-19).

• Normotensive (BP: 90/60mmHg - 140/90mmHg). Sufficiently treated hypertensive subjects will be included.

• BMI: 19 - 34,9 kg/m2

• Age: 18 - 30 years

• Fluent in German

• IC as documented by signature

Locations
Other Locations
Switzerland
University of Basel, Reserach Cluster Molecular and Cognitive Neurosciences
RECRUITING
Basel
Contact Information
Primary
Christiane Gerhards, MD
christiane.gerhards@unibas.ch
+41 61 207 0244
Time Frame
Start Date: 2025-05-22
Estimated Completion Date: 2026-07
Participants
Target number of participants: 38
Treatments
Active_comparator: Intervention
Experimental: Fampridin SR~Active study medication consists of 15 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.~There will be a washout period of at least 6.5 days equaling over 20 half-lives of the active substance fampridine (t½ = 6 h) between experimental and control intervention and up to 28 days depending on the individual scheduling of each subject.
Placebo_comparator: Other intervention
15 Identically looking placebo tablets consisting of widely identical additives formulated for oral administration.
Related Therapeutic Areas
Sponsors
Collaborators: Clinical Trial Unit, University Hospital Basel, Switzerland
Leads: University of Basel

This content was sourced from clinicaltrials.gov